Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy. The study aims to assess the efficacy of riliprubart compared to IVIg in adults with CIDP who are on maintenance IVIg treatment, highlighting its potential to offer a new therapeutic option for this condition.
The study tests riliprubart, an experimental drug administered intravenously, against the standard IVIg treatment. Riliprubart is intended to provide an alternative treatment option for CIDP patients.
This interventional study is randomized with a parallel assignment and employs quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary goal is treatment, with a double-blind treatment period followed by an open-label phase.
The study began on August 21, 2024, with a primary completion date estimated for 2025. The latest update was submitted on August 18, 2025, indicating ongoing recruitment and progress in the study.
This update may positively influence Sanofi’s stock performance by showcasing its commitment to advancing CIDP treatment options. Investors may view this as a strategic move to strengthen its position in the pharmaceutical market, potentially impacting competitor dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.